



About the Joint- Funded Award Opportunity:

The Stem Cell Network (SCN) is excited to collaborate with Breakthrough T1D in conjunction with their Canadian affiliate, JDRF Canada, in this funding competition to offer Joint-Funding Award opportunities for type 1 diabetes (T1D) translational research. SCN's partnership with Breakthrough T1D represents a commitment to leveraging collective resources to support research that will advance treatments based on regenerative medicine for type 1 diabetes, and lead to improved outcomes for people living with this condition.

About Breakthrough T1D:

Breakthrough T1D is a global leader in the search for an end to type 1 diabetes, through both research funding and advocacy. JDRF Canada is the Canadian affiliate of Breakthrough T1D and the primary point of contact for this funding opportunity. In addition to curing type 1 diabetes, part of their mission is to help those living with type 1 diabetes today to live healthier, easier, and safer lives. Their mission is realized by supporting research in two core areas: Cure T1D and Improve Lives. Breakthrough research, transformative therapies, emerging technologies, translational opportunities, and clinical trials are prioritized.

Funds Available:

SCN and Breakthrough T1D are each providing up to \$2,000,000 CAD to jointly fund regenerative medicine projects in the T1D area. Projects selected for joint funding will receive awards valued at up to 120% of SCN standard suite of awards. Each project selected for joint partnered funding will be supported 50-50 by Breakthrough T1D and SCN.

The following SCN programs will be available for Joint-Funding Award by SCN and Breakthrough T1D:

- **Accelerating Clinical Translation Award:** up to \$780,000 per award over 2 years
- **Clinical Trials Awards:** up to \$1,320,000 per award over 3 years
- **Fueling Biotechnology Partnership Award:** up to \$516,000 per award over 2 years

- **Impact Awards:** up to \$324,000 per award over 2 years
- **Impact Awards: ELSI & HE Stream:** up to \$258,000 per award over 2 years

Joint-partnering specific eligibility and criteria:

- Scope: Breakthrough T1D will support projects relevant to developing or testing islet replacement therapies for type 1 diabetes. To be eligible for Breakthrough T1D funding, projects must be focused on translational themes from one or more of the following topics:
 - Developing or testing therapeutic approaches that are regenerative in nature, including cell and/or gene therapies, tissue engineering technologies or biomaterials;
 - Using stem cells as a necessary component for the generation of functional cell types;
 - Investigating a small molecule or biologic that acts on or is dependent on endogenous stem cells for its therapeutic effect
 - Investigating the social, ethical and/or economic implications of regenerative medicine therapies.

Note: Investigative projects focused on addressing the role and function of stem cells in a tissue or disease **are not considered in scope** for this Joint-Funding Award opportunity.

- The eligibility and criteria described in SCN's standard programs will also apply.
- All applications to this joint partnering opportunity will be evaluated through SCN's two-stage peer review process.
- In addition to the support offered through this joint initiative, applicants should seek other eligible cash or in-kind partnering.
- The Breakthrough T1D budget allocation must conform with Breakthrough T1D's [eligible expenditures policy](#).

- A maximum of 20% of the Breakthrough T1D budget allocation can be used to support research outside of Canada. SCN funds cannot be used to support research outside of Canada.
- Applications that do not meet the Joint-Funded Award eligibility requirements will be considered for funding through SCN's standard suite of programs.

Funding conditions:

- All awards funded through this joint-partnering opportunity will be subject to separate grant agreements between the host institutions of projects selected for joint funding and SCN and Breakthrough T1D.
- Information on Breakthrough T1D's standard terms and conditions, including regarding intellectual property and allowable costs, can be obtained [here](#). It is recommended that applicants seek this information prior to preparing their application and budget. Please note that Indirect costs will not be offered by Breakthrough T1D through this funding opportunity. Indirect costs not requested can be included as institutional in-kind support.
- Breakthrough T1D's payment schedule will be determined on a case-by-case basis and may not align with SCN's payment schedule.
- All funded awards will be subject to SCN's continual review process.